MeiraGTx Holdings plc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
-1.0%projected annual EPS growth
Analyst Coverage
7analysts covering
FY EPS (est.)
$0.51next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Earnings Release | 16 Nov 2026 |
Monitoring Framework
Key Performance Indicators
Cash Runway Quarterly2KTarget: 2H 2028
Service Revenue Quarterly300KTarget: Commercial Product Launch
Watch Items
- AAV2-hAQP1 Phase 2 AQUAx2 Clinical Trial Data ReadoutTrigger: Q2 2027Action: Evaluate clinical efficacy and safety data to support potential BLA filing by mid-2027.
- bota-vec Regulatory SubmissionsTrigger: Next 2 YearsAction: Monitor progress of regulatory filings in the U.S., EU, UK, and Japan following reacquisition from J&J.
- Eli Lilly Collaboration MilestonesTrigger: Up to $135 million near-termAction: Track AAV-AIPL1 clinical and regulatory progress to trigger milestone payments.
Research as of 19 Jun 2026